ModeX’s Dr. John Mascola will be at World Vaccine Congress 2026 to discuss the development of unique tetravalent antibodies for COVID and influenza highlighting ModeX’s work in this area. If you are at the Congress, drop in and join the conversation. @jrmascola
Don’t miss ModeX Therapeutics’s poster presentation at #ESMO25 and stay at the forefront of research with multispecific antibodies. Learn more about our pipeline here:
bit.ly/42LYd80
1
100
Join Us: Jefferies Global Healthcare Conference: OPKO Health, Inc. (OPK):
opko.com/investors/news-even…
#ICYMI Modex was thrilled to be presenting preclinical data on MDX2001, a tetraspecific for targeting solid tumor malignancies today at #SITC24 Details found here: bit.ly/40r06qj
$OPK
ModeX is excited to share information about MDX2001, a novel tetraspecific T cell engager for treatment of advanced solid tumors, at #SITC24 on Nov. 8.
Stop by our posters in the Exhibit Hall to learn more. Details found here: bit.ly/40r06qj
Tags: $OPK
Happy International Women's Day! Today we celebrate each of the incredible women at ModeX for their commitment to advancing science and creating new medicines. We're grateful to be able to empower each other on our path to making a difference for patients together. #IWD24
Today we announced results from a Phase 1 clinical study of SAR441236, a trispecific antibody for the treatment and prevention of #HIV, at the 2024 Conference on Retroviruses and Opportunistic Infections (#CROI). Learn more: bit.ly/4c2Jzw3
On #EmployeeAppreciationDay we thank the ModeX team who embody our commitment to creating innovative medicines with their drive for scientific excellence, mission-oriented focus and collaborative spirit. We’re endlessly proud of all the work that you do! #biotechjobs #MakingModeX
At ModeX Alicia integrates the team's many skills to progress our goal of developing transformative #multispecific medicines. Managing projects on the oncology team, she treats every day as an opportunity to advance our pipeline.
More on us: bit.ly/47Pb0GT #biotechjobs
1
91
By combining multiple antigen-binding sites into a single molecule, our multispecific antibodies are as space-efficient as they can be. Our MSTAR platform simplifies gene expression, allowing for more efficient manufacturing & gene-based antibody delivery. bit.ly/3FOQRoe








